KT032 / Nanjing KATI - LARVOL DELTA

Kati Medicine: MSLN CAR-T new drug obtained clinical approval [Google translation] (163.com) - "On September 26, 2023, the clinical trial application of Nanjing Kati Medical Technology Co., Ltd. (Katik Medicine) cell therapy product (KT032 cell injection) was implicitly approved by the National Medical Products Administration (NMPA). The indications are: Cortin-positive advanced ovarian cancer (acceptance number: CXSL2300444)."

New trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor